TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15451330

Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg, twice a day for 5 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 48
Study: 11446878

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) with amoxicillin (500 mg t.i.d.)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Rabeprazole (10 mg b.i.d.) with amoxicillin (500 mg t.i.d.)
Number of subjects: 199
Study: 10209375

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural fentanyl 100 micrograms
Number of subjects: 0
Study: 7600216

Group type: EXPERIMENTAL
Intervention: PUVA therapy (8‐methoxypsoralen 0.6 mg/kg administered orally 2 hours before irradiation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control sites (not treated with PUVA)
Number of subjects: 18
Study: 2192446

Group type: EXPERIMENTAL
Intervention: Lateral incision (new approach)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Midline incision (prior standard approach)
Number of subjects: 37
Study: 365428

Group type: EXPERIMENTAL
Intervention: Prazosin (17 mg) substituted for methyldopa
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prazosin (14 mg) added to methyldopa and hydrochlorothiazide
Number of subjects: 21
Study: 31473913

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 31094262

Group type: EXPERIMENTAL
Intervention: Dry short-term heat acclimation (STHA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Humid short-term heat acclimation (STHA)
Number of subjects: 11
Study: 28029362

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 2887
Study: 26157049

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 24274190

Group type: EXPERIMENTAL
Intervention: Acticoat™
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acticoat™ combined with Mepitel™
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mepilex Ag™
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study: 21266910

Group type: EXPERIMENTAL
Intervention: HAART-BF
Number of subjects: 1719

Group type: COMPARATOR
Intervention: ZDV-BF
Number of subjects: 1719

Group type: COMPARATOR
Intervention: ZDV-FF
Number of subjects: 1719
Study: 19201180

Group type: EXPERIMENTAL
Intervention: Fish-flour spread rich in n-3 long-chain polyunsaturated fatty acids
Number of subjects: 183
Study: 17574481

Group type: EXPERIMENTAL
Intervention: Probiotic gum group (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Xylitol gum group (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Probiotic + xylitol gum group (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo gum group (Group D)
Number of subjects: 80
Study: 14959808

Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (SCG)
Number of subjects: 0
Study: 11845604

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (with possible addition of enalapril and hydrochlorothiazide)
Number of subjects: 4695

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine
Number of subjects: 4695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study: 11767208

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day with vitamin E 200 mg per day for 3 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day for 3 weeks
Number of subjects: 26
Study: 9284857

Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide 3.25 mg at 0 hours and again at 6 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide 0.5 mg/hr for 6 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Loading dose of 0.5 mg bumetanide at 0 hours followed by a bolus regimen
Number of subjects: 8
Study: 8117360

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 15
Study: 3101839

Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2199358

Group type: EXPERIMENTAL
Intervention: dihydroergotoxine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 80
Study: 31957130

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) session before procedure
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no Music Therapy)
Number of subjects: 159
Study: 29999194

Group type: EXPERIMENTAL
Intervention: Muffins with 20 g flaxseed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muffins with 30 g flaxseed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Muffins with 0 g flaxseed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muffins with flax at any level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muffins stored at -20 °C for 6 months
Number of subjects: 0
Study: 28327983

Group type: EXPERIMENTAL
Intervention: Coil embolization with adjunctive techniques (e.g., balloon remodeling)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Coil embolization
Number of subjects: 132
Study: 26512849

Group type: EXPERIMENTAL
Intervention: Inferior oblique muscle recession
Number of subjects: 13
Study: 23611095

Group type: EXPERIMENTAL
Intervention: Restrictive positive fluid balance strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-restrictive positive fluid balance strategy
Number of subjects: 60
Study: 21175801

Group type: EXPERIMENTAL
Intervention: Intragastric infusion of 300 mL of 0.1 mol/L hydrochloric acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water infusion (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intragastric infusion of 0.1 mol/L hydrochloric acid
Number of subjects: 6
Study: 19236410

Group type: EXPERIMENTAL
Intervention: Lupine-enriched pasta
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo pasta
Number of subjects: 12
Study: 17485422

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks
Number of subjects: 306

Group type: COMPARATOR
Intervention: Conventional disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 306

Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 306
Study: 15152293

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (4 mg/h continuously from admission to 48 h after PTCA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no nicorandil treatment)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 12466679

Group type: COMPARATOR
Intervention: Clonidine (0.1 mg every 6 h, with one dose on-site each day and others taken home)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg IM daily)
Number of subjects: 124
Study: 9433338

Group type: EXPERIMENTAL
Intervention: Fixed haloperidol doses intended to achieve plasma levels of 8‐18 ng/ml
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fixed haloperidol doses intended to achieve plasma levels of 25‐35 ng/ml
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lower dose reassignment for patients whose BPRS scores failed to improve by 30%
Number of subjects: 66

Group type: COMPARATOR
Intervention: Higher dose reassignment for patients whose BPRS scores failed to improve by 30%
Number of subjects: 66
Study: 7655699

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2560555

Group type: EXPERIMENTAL
Intervention: RU 486 (glucocorticoid antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (healthy volunteers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 0
Study: 794895

Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: dextroamphetamine
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study: 31798985

Group type: EXPERIMENTAL
Intervention: EmOC&NC training
Number of subjects: 127
Study: 27993387

Group type: EXPERIMENTAL
Intervention: Simvastatin (SIMVA) 20 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24852756

Group type: EXPERIMENTAL
Intervention: Collagen peptides isolated from pork skin (PCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen peptides isolated from bovine bone (BCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23635625

Group type: EXPERIMENTAL
Intervention: Serum hCG follow-up
Number of subjects: 376

Group type: COMPARATOR
Intervention: Ultrasound follow-up
Number of subjects: 376
Study: 20617886

Group type: EXPERIMENTAL
Intervention: High performers (young and old)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low performers (young and old)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 19122553

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric bupivacaine 0.5% and 5 microg sufentanil intrathecally
Number of subjects: 132

Group type: COMPARATOR
Intervention: Epidural anaesthesia with ropivacaine 0.75% and 10 microg sufentanil epidurally
Number of subjects: 132
Study: 17545717

Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir 1400/200 mg once a day plus TDF 300 mg once a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir 1400/100 mg once a day plus TDF 300 mg once a day
Number of subjects: 30
Study: 14722034

Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel (two dose levels)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 53
Study: 11468730

Group type: EXPERIMENTAL
Intervention: Initial daily induction with 10 million units (MU) IFNalpha‐n1, s.c., for 13 months followed by intermittent therapy (group 1, n = 50)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Continuous IFNalpha‐n1 therapy with initial daily induction (group 2, n = 52)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard IFNalpha‐n1 therapy (group 3, n = 53)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Initial daily induction with 10 MU IFNalpha‐n1 (group 1)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Continuous IFNalpha‐n1 therapy (group 2)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard IFNalpha‐n1 therapy (group 3)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Induction therapy (group 1)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Daily high‐dose treatment
Number of subjects: 155
Study: 9875905

Group type: EXPERIMENTAL
Intervention: PAFra (120 mg iv every 12 hrs over a 4-day period)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: PAFra
Number of subjects: 609

Group type: COMPARATOR
Intervention: PAFra and Placebo
Number of subjects: 609
Study: 7986594

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 81
Study: 2647818

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with freeze-dried birch-pollen antigens for 18 months, cumulative dose of 280 x 10(6) biologic units
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study: 30340895

Group type: EXPERIMENTAL
Intervention: Low intensity exercise protocol (50% Wmax)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strenuous exercise at 70% Wmax in dehydrated state
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strenuous dehydrated protocol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High intensity exercise at 70% Wmax in hydrated condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest protocol
Number of subjects: 15
Study: 27670203

Group type: EXPERIMENTAL
Intervention: Desloratadine plus prednisolone (single dose followed by two of placebo for 7 days)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Dexchlorpheniramine plus betamethasone (three daily doses for 7 days)
Number of subjects: 210
Study: 26305866

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAID use
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Chronic musculoskeletal pain
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: General musculoskeletal complaints
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Headaches
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Sciatica
Number of subjects: 4726

Group type: EXPERIMENTAL
Intervention: Atherosclerotic disease
Number of subjects: 4726
Study: 23864517

Group type: EXPERIMENTAL
Intervention: Occupation-based meta-cognitive strategy-training program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Education about brain health and cognitively stimulating exercises
Number of subjects: 19
Study: 21640518

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy with chemotherapy (RT-CHT)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy alone (RT)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall group (RT-CHT and RT)
Number of subjects: 600
Study: 19410064

Group type: EXPERIMENTAL
Intervention: NA Internal
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: NA External
Number of subjects: 177

Group type: COMPARATOR
Intervention: NR
Number of subjects: 177
Study: 17632307

Group type: EXPERIMENTAL
Intervention: Synergeyes lenses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Soflens 66 Toric lenses
Number of subjects: 50
Study: 15343163

Group type: EXPERIMENTAL
Intervention: NiCr alloy, vacuum casting (VVC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CoCr alloy, vacuum casting (WVC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NiCr alloy, acetylene‐oxygen flame casting (VFC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CoCr alloy, acetylene‐oxygen flame casting (WFC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Commercially pure Ti alloy (Ti)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (VVC, WVC, VFC, WFC)
Number of subjects: 40
Study: 11403243

Group type: EXPERIMENTAL
Intervention: Exercise programming (Study group, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional outpatient therapy (Home group, n = 10)
Number of subjects: 21
Study: 9743818

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS 4&6, 3 x 400 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 8036825

Group type: EXPERIMENTAL
Intervention: PDEV vaccine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HDCV vaccine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (subjects aged 11-25 years)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PDEV and HDCV vaccines
Number of subjects: 2
Study: 2656601

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30910489

Group type: EXPERIMENTAL
Intervention: Nonanimal hyaluronic acid (NASHA) 1 mL intra-articular injection
Number of subjects: 37
Study: 28194823

Group type: EXPERIMENTAL
Intervention: Smartphone viewing of CXR images
Number of subjects: 21

Group type: COMPARATOR
Intervention: Computer screen viewing of CXR images
Number of subjects: 21
Study: 25171195

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 23609383

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study: 20511127

Group type: EXPERIMENTAL
Intervention: Proprioceptive training incorporated into the regular training regimen of the training group.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy athletes of other sports).
Number of subjects: 20
Study: 18422164

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray < or =400 microg/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray 1 ‐ <3 year
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray 3 ‐ <5 year
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray > or =5 year
Number of subjects: 36
Study: 15926303

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 2.5 ATA
Number of subjects: 23
Study: 12651647

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (Vitamin C 500 mg)
Number of subjects: 240
Study: 11185633

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amlodipine 10 mg plus Telmisartan 120 mg
Number of subjects: 12
Study: 8858323

Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence spectroscopy
Number of subjects: 0
Study: 8348256

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg for children younger than one year and 1 mg for older children)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 3538106

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29526139

Group type: EXPERIMENTAL
Intervention: Centrifugal-flow pump
Number of subjects: 366

Group type: COMPARATOR
Intervention: Axial-flow pump
Number of subjects: 366
Study: 24768240

Group type: EXPERIMENTAL
Intervention: Ahmed FP7 Glaucoma Valve (AGV)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Baerveldt Glaucoma Implant (BGI)
Number of subjects: 276
Study: 22500700

Group type: EXPERIMENTAL
Intervention: Real rMS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham rMS
Number of subjects: 34
Study: 19740120

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18633764

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (wash-out period)
Number of subjects: 32
Study: 15719703

Group type: EXPERIMENTAL
Intervention: Tacrolimus II microparticle enzyme immunoassay (MEIA)
Number of subjects: 1121
Study: 12121486

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg by mouth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol (50 microg/day)
Number of subjects: 0
Study: 11829851

Group type: EXPERIMENTAL
Intervention: Ordinary operation (group I)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Operation after ligation of drained vessels (group II)
Number of subjects: 172
Study: 7883844

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CrossLaps ELISA baseline values
Number of subjects: 180
Study: 2676343

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 332349

Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy (50 patients)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Extensive 'systemic' radiotherapy (49 patients)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy with total‐body irradiation (34 patients)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Combination chemotherapy (34 patients)
Number of subjects: 99
Study: 30458655

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 8 g (1.1:1 ratio)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (6 g citric acid)
Number of subjects: 19
Study: 31414632

Group type: EXPERIMENTAL
Intervention: Direct microscopy, culture, and PCR methods for diagnosing Blastocystis spp.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SSU rRNA gene sequencing and STS-PCR methods for subtype distribution analysis.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of demographic characteristics and clinical findings between positive and negative cases.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of symptoms and subtypes of Blastocystis spp.
Number of subjects: 100
Study: 29074509

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 102
Study: 27137716

Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naloxegol 60mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naloxegol 125mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naloxegol 250mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23620319

Group type: EXPERIMENTAL
Intervention: Sonographically guided blocks
Number of subjects: 415

Group type: COMPARATOR
Intervention: Nerve stimulator guided blocks
Number of subjects: 415